Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Neurocrine Biosciences
NBIX
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$118.35
0
0.00%
Pre-Market: Sep 20, 4:04 PM EDT
15 minutes delayed
Get Report
Comment
Neurocrine Biosciences (NBIX) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Neurocrine Biosciences (NASDAQ:NBIX) Stock
Neurocrine Biosciences Stock (NASDAQ: NBIX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, September 16, 2024
Cantor Fitzgerald Reiterates Overweight on Ne...
Benzinga Newsdesk
Friday, September 13, 2024
Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint
Vandana Singh
Thursday, September 12, 2024
Neurocrine Biosciences Provides Update on ERU...
Benzinga Newsdesk
Monday, September 09, 2024
Decoding 19 Analyst Evaluations For Neurocrine Biosciences
Benzinga Insights
Barclays Maintains Overweight on Neurocrine B...
Benzinga Newsdesk
Sunday, September 08, 2024
Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio?
Lekha Gupta
Monday, September 02, 2024
Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio?
Lekha Gupta
Thursday, August 29, 2024
Neurocrine Biosciences shares are trading hig...
Benzinga Newsdesk
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
Vandana Singh
Cantor Fitzgerald Maintains Overweight on Neu...
Benzinga Newsdesk
RBC Capital Maintains Sector Perform on Neuro...
Benzinga Newsdesk
NVIDIA To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Thursday
Avi Kapoor
HC Wainwright & Co. Reiterates Buy on Neurocr...
Benzinga Newsdesk
Needham Reiterates Hold on Neurocrine Bioscie...
Benzinga Newsdesk
Piper Sandler Upgrades Neurocrine Biosciences...
Benzinga Newsdesk
BMO Capital Maintains Market Perform on Neuro...
Benzinga Newsdesk
Wednesday, August 28, 2024
Nasdaq Down Over 1%; Foot Locker Shares Tumble After Q2 Results
Avi Kapoor
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Vandana Singh
US Stocks Mixed; JM Smucker Slashes Annual Guidance
Avi Kapoor
Neurocrine Biosciences shares are trading low...
Benzinga Newsdesk
Neurocrine Biosciences Announced Positive Top...
Benzinga Newsdesk
Tuesday, August 27, 2024
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Anthony Noto
Monday, August 19, 2024
Evaluating Neurocrine Biosciences: Insights From 15 Financial Analysts
Benzinga Insights
Jefferies Maintains Buy on Neurocrine Bioscie...
Benzinga Newsdesk
Tuesday, August 13, 2024
9 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Wednesday, August 07, 2024
JP Morgan Maintains Overweight on Neurocrine ...
Benzinga Newsdesk
Monday, August 05, 2024
HC Wainwright & Co. Maintains Buy on Neurocri...
Benzinga Newsdesk
Friday, August 02, 2024
RBC Capital Maintains Sector Perform on Neuro...
Benzinga Newsdesk
Guggenheim Maintains Buy on Neurocrine Biosci...
Benzinga Newsdesk
Citigroup Maintains Neutral on Neurocrine Bio...
Benzinga Newsdesk
Oppenheimer Maintains Outperform on Neurocrin...
Benzinga Newsdesk
Barclays Maintains Overweight on Neurocrine B...
Benzinga Newsdesk
Baird Maintains Outperform on Neurocrine Bios...
Benzinga Newsdesk
Thursday, August 01, 2024
A Closer Look at 7 Analyst Recommendations For Neurocrine Biosciences
Benzinga Insights
Neurocrine Biosciences shares are trading hig...
Benzinga Newsdesk
Needham Reiterates Hold on Neurocrine Bioscie...
Benzinga Newsdesk
Neurocrine Biosciences Raises INGREZZA FY24 N...
Benzinga Newsdesk
Neurocrine Biosciences Q2 2024 Adj. EPS $1.63...
Benzinga Newsdesk
Thursday, July 25, 2024
Cantor Fitzgerald Reiterates Overweight on Ne...
Benzinga Newsdesk
Needham Reiterates Hold on Neurocrine Bioscie...
Benzinga Newsdesk
Thursday, July 18, 2024
Neurocrine Biosciences Launches INGREZZA SPRI...
Benzinga Newsdesk
Friday, July 12, 2024
Morgan Stanley Maintains Overweight on Neuroc...
Benzinga Newsdesk
Wednesday, July 10, 2024
Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences
Benzinga Insights
JP Morgan Maintains Overweight on Neurocrine ...
Benzinga Newsdesk
Monday, July 01, 2024
Neurocrine Biosciences' Crinecerfont Receives...
Benzinga Newsdesk
Wednesday, June 12, 2024
Morgan Stanley Maintains Overweight on Neuroc...
Benzinga Newsdesk
Monday, June 03, 2024
Neurocrine Biosciences shares are trading hig...
Benzinga Newsdesk
Neurocrine Biosciences Presented Data For Its...
Benzinga Newsdesk
Neurocrine Biosciences' Crinecerfont Shows Re...
Benzinga Newsdesk
Wednesday, May 29, 2024
Wedbush Reiterates Outperform on Neurocrine B...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch